Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Assistance Publique - Hôpitaux de Paris
With
It's a prospective randomized double blind, multicentre, parallel-group in a 1:1 ratio, controlled and superiority trial. The primary objective is to assess the effect of a Fluticasone Propionate associated with Salmeterol using inhalation chamber compared to placebo on respiratory function at 6 months in children over six years of age who underwent allogeneic hematopoietic stem cell transplantation with a decline of FEV1 ≥ 10% from pre transplantation. The primary criterion will be the difference in the FEV1% predicted value from inclusion to 6 months following the initiation of treatment. To assess the effect of a Fluticasone Propionate associated with Salmeterol using inhalation chamber compared to placebo in children over six years old underwent allogeneic hematopoietic stem cell transplantation with a decline of FEV1 ≥ 10% from pre transplantation baseline to 6 months following the initiation of treatment, and 6 months after the end of treatment, on pulmonary function, respiratory symptoms, Bronchiolitis Obliterative Syndrome (BOS) rate, oral steroid exposure and occurrence of infections; To assess potential confounding factors associated to the 6-months inhaled treatment efficacy from baseline to 12 months, especially: \- GVHD (Graft Versus Host Disease) occurrence, severity and treatment (steroid dose exposure, calcineurins inhibitors dose, second line of GVHD treatment); To assess the safety and tolerability of the treatment at baseline, M1, M3 and M6 following the initiation of treatment All endpoints were collected at baseline, randomization, 1, 3, 6 months during the treatment period, and then 3, 6 months after the end of the treatment. 1. Endpoints relative to respiratory symptoms : * dyspnea will be evaluate at the NYHA (New York Heart Association) scoring; * step test (patient climb up and down step during three minutes at the frequency of 30/mn) : Respiratory rate, dyspnea Heart rate, SaO2 (oxygen saturation) during the exercise. 2. Endpoints relative to pulmonary function : * FEV1 (Forced expiratory volume) VC (Vital Capacity) , TLC (Total Lung capacity) , RV (Residual volume), FRC (Functional Residual Capacity), sRaw (specific airway resistance) DLCO (diffusing capacity of the lungs) using a similar method of measurement for static lung volumes (plethysmography) * Number of patients presented with BOS defined as the absence of infection, and FEV1 \< 75% predicted, and the FEV1/ FVC \< 0.7, and the RV \>120% or air trapping or bronchiectasis or small airways thickening on computed tomography 3. Endpoints relative to GVHD : * Acute and Chronic GVHD manifestations defined on NIH consensus with scoring; * First line of treatment: cumulative dose of corticosteroid systemic exposure and cumulative dose of calcineurins inhibitors. * Second line of GVHD treatment exposure will be assessed using the other type of treatment. 4. Endpoints relative to respiratory infections : \- Number of adverse events. 5. Endpoints relative to safety and tolerance: * Adverse events during the study period such as treatment tolerance, thrush, death. The investigators will study patients over six years of age who underwent allogeneic hematopoietic stem cell transplantation with a decline of FEV1 ≥10% from pre transplantation. The choice of this range of age is motivated by the fact that PFTs (Pulmonary Function Test) requires a degree of cooperation that is age dependent, only children who are 6 years of age or older are able to realize reproducible PFTs. For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber \- For children between 12 to 17 years (\> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 6 to 11 years (\< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (\> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
Age
6–17
Sex
ALL
Healthy volunteers
Not accepted
